Effect of Sublingual Immunotherapy in Patients With Atopic Dermatitis
Status:
Completed
Trial end date:
2020-06-26
Target enrollment:
Participant gender:
Summary
Atopic dermatitis (AD) is a chronic and recurrent inflammatory disease, prevalent between 1
and 20% in the world population, with a predominance of childhood, but which may be present
in adult life. AD results from a complex interaction between genetic and environmental
factors, with the presence of a defect in the skin barrier and deregulation of the immune
response, culminating in an inflammatory response in the skin predominantly type 2. Disease
control is based on restoring skin hydration, smoothing itching and controlling the process
specific sensitizing agents such as inhalant allergens and foods that may pathogenesis of the
disease. In selected patients who present IgE mediated response to inhalant allergens,
allergen-specific immunotherapy can be effective. Classically, the subcutaneous route is the
most used, however, sublingual immunotherapy (SLIT) has been used in increasing form. There
are still few studies on the efficacy and safety of SLIT in atopic dermatitis. Therefore, the
present study aims to to investigate the role of SLIT in the management of patients with AD
allergic mites, through a randomized, double-blind and placebo-controlled study
Phase:
Phase 4
Details
Lead Sponsor:
Casa Espirita Terra de Ismael
Collaborator:
Fundação de Amparo à Pesquisa do Estado de São Paulo